Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

News SummaryMost relevantAll newsSector newsTweets

Spectrum Pharmaceuticals, Inc. : Hagens Berman Notifies Spectrum Pharmaceuticals Investors of Pending Class-Action Lawsuit and May 13, 2013, Lead Plaintiff Deadline

share with twitter share with LinkedIn share with facebook
share via e-mail
03/22/2013 | 02:35pm CET

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or "The Company") following the filing of a class-action lawsuit on behalf of investors. The firm encourages those who have suffered losses to contact Hagens Berman Partner Reed Kathrein, who is leading the Firm's investigation, by emailing [email protected].

A class-action lawsuit filed in U.S. District Court identifies a class of Spectrum investors who purchased stock in the company between August 8, 2012, and March 12, 2013, inclusive (the "class period"). Those who suffered significant losses and wish to move to be a lead plaintiff may also contact the firm by calling (510) 725-3000.

Investors who wish to serve as lead plaintiff in the case must move the court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On March 12, 2013, Spectrum disclosed to investors that it would significantly lower its 2013 revenue guidance on concerns that sales of its drug FUSILEV would be lower than expected. Following the disclosure, Spectrum's stock price fell dramatically, from a close of $12.43 per share on March 12 to a close of $7.79 per share on March 13. The stock has continued to trade at or around $7.00 since the disclosure.

Hagens Berman's investigation centers around whether Spectrum knew and failed to disclose to investors concerns about the sales of FUSILEV.

"We are concerned that Spectrum knew that generic competition would substantially impact the company's revenues and failed to disclose these concerns to investors," said Mr. Kathrein. "We believe the company's alleged failure to come clean with investors about these issues may have artificially inflated the stock price, resulting in very significant investor losses."

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

More information about this investigation is available at http://www.hb-securities.com/investigations/SPPI.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357
[email protected]

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
12/05 SPECTRUM PHARMACEUTICALS : Highlights 15 Abstracts at the 59th Annual Meeting of..
12/04 CASI PHARMACEUTICALS : Announces Poster Presentation At The 2017 San Antonio Bre..
12/04 SPECTRUM PHARMACEUTICALS : Highlights 15 Abstracts at the 59th Annual Meeting of..
11/17 SPECTRUM PHARMACEUTICALS, INC. : Today’s Research Reports on Trending Tickers: S..
11/16 CASI PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results
11/08 SPECTRUM PHARMACEUTICALS, INC. : Stonegate Capital Partners Updates Coverage on ..
11/08 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Jefferies 2017 Lon..
11/02 SPECTRUM PHARMACEUTICALS : Pharma reports 3Q loss
11/02 SPECTRUM PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
11/02 SPECTRUM PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results and Pipe..
More news
News from SeekingAlpha
12/07 Notable BioSci Mover - October 6, 2017 Report
11/30 BIOTECH : Biding Its Time
11/19 AN INTEGRATED RESEARCH ON GLOBAL BLO : Is Voxelotor The Answer For Sickle Cell D..
11/02 Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shrotriya on Q3 2017 Results - Ea..
11/02 Spectrum Pharmaceuticals beats by $0.13, beats on revenue
Financials ($)
Sales 2017 133 M
EBIT 2017 -73,8 M
Net income 2017 -84,6 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 14,4x
Capi. / Sales 2018 14,7x
Capitalization 1 905 M
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Technical analysis trends SPECTRUM PHARMACEUTICALS,
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Average target price 28,7 $
Spread / Average Target 52%
EPS Revisions
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph W. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Luigi Lenaz Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%22 034
LONZA GROUP54.74%19 270